Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study

OBJECTIVE: Apatinib mesylate is a novel vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which has exhibited good safety and efficacy in several types of solid tumors. The present study aimed to assess the clinical efficacy and safety of apatinib combined with chemotherapy and conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Qiufen, Sun, Yawen, Kong, Enqi, Rao, Linli, Chen, Jinlong, Wu, Qian, Zhang, Tingting, Liu, Naifu, Li, Mingjiang, Sun, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220314/
https://www.ncbi.nlm.nih.gov/pubmed/32176061
http://dx.doi.org/10.1097/MD.0000000000019372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220314/
https://www.ncbi.nlm.nih.gov/pubmed/32176061
http://dx.doi.org/10.1097/MD.0000000000019372

Ejemplares similares